Skip to main content
. 2020 Oct 27;8(2):e001493. doi: 10.1136/jitc-2020-001493

Figure 2.

Figure 2

Survival of mice bearing established B16-F10 melanoma treated with SEG/SEI is shown. (A) C57BL/6 or (B) HLA-DQ8 tg mice received 2.5×105 B16-F10 cells IP on day 0. SEG/SEI, 50 µg of each, was administered ip on days 6 and 9. Controls received B16-F10 tumor cells but no treatment (Kaplan-Meier with log-rank n=10–11). (C) On day 160, 4 surviving mice from (B) were rechallenged with 2.5×105 B16-F10 cells ip. Untreated controls received B16-F10 tumor alone. (D) an additional five mice from (B) that survived 160 days were challenged with 2.5×105 Lewis lung carcinoma cells (LLC). Untreated controls received LLC cells alone (Kaplan-Meier with Log-rank). Histopathology analysis of B16-F10 omental tumors on day 13 after tumor inoculation from (E) untreated and (F) SEG/SEI -treated HLA-DQ8 TG mice is shown (H&E ×10 magnification). (G) HLA-DQ8 tg mice received 2.5×105 live B16-F10 cells ip on day 0, followed by the treatment with SEG/SEI, 50 µg of each, on days 6 and 9 and ip injections of anti-CD4, anti-CD8 and anti-lgG2b isotype control as shown (red arrows) (Kaplan-Meier with Log-rank, n=4–5). *P<0.05, **p<0.01.